New reagent for determination of Lactate Dehydrogenase (LDH)
LDH 21 FS, a new assay for determination of Lactate Dehydrogenase (LDH) was launched in 2021. Increased LDH activities are found in a variety of pathological conditions such as myocardial infarction, liver diseases, blood diseases, and cancer or muscle diseases. Increased serum LDH values are also one of the abnormal diagnostic parameters in COVID-19 patients with a severe or fatal course of disease.
For LDH, a standardized reference method by IFCC is available. The new LDH 21 FS uses a modified IFCC method that shows optimized performance. An improved calibration and onboard stability, as well as a wide measuring range, high precision at clinical cut-offs and minimized interferences by common blood components, characterize the reagent.
The new test may be applied on all automated clinical chemical analyzers and shows good comparability with commercially available methods for the determination of LDH.
Exhibitor: DiaSys Diagnostic Systems GmbH